Chronic Myeloid Leukemia Faceoff: Fred Hutchinson Cancer Center vs City of Hope

home / face-off / chronic-myeloid-leukemia-faceoff-fred-hutchinson-cancer-center-vs-city-of-hope

Experts from the Fred Hutchinson Cancer Center and City of Hope form two teams and go head-to-head in this review of the latest datasets in the chronic myeloid leukemia treatment landscape.

Experts on CML

EP. 1: Team Introductions: CML Experts From the Fred Hutchinson Cancer Center and City of Hope

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS
September 12th 2023

An overview of the program agenda and introduction of expert panelists from the Fred Hutchinson Cancer Center and City of Hope teams.

Experts on CML

EP. 2: Optimizing Ponatinib in CML: Understanding AOEs in the PACE Trial

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS
September 12th 2023

A retrospective analysis of arterial occlusive events in the PACE trial, shedding light on risk factors and management strategies for ponatinib treatment in CML patients.

Experts on CML

EP. 3: Dosing Strategies and Disease Control With Ponatinib: The OPTIC Study

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS
September 19th 2023

An expert explores findings of the OPTIC study, revealing optimal dosing strategies for ponatinib in CML treatment, including insights into dose reduction and patient response based on T315I mutation status.

Experts on CML

EP. 4: Cross Q&A: Dosing Ponatinib in CML to Balance Efficacy and Cardiovascular Safety

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS
September 19th 2023

Experts discuss dosing strategies and risk factors for arterial occlusive events in ponatinib treatment for chronic myeloid leukemia, emphasizing the importance of balancing disease control and patient safety.

Experts on CML

EP. 5: Cross Q&A: Managing Cardiovascular Risks in CML Treatment

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS
September 26th 2023

A panel of experts discusses the challenges and considerations surrounding cardiovascular risks associated with ponatinib treatment for chronic myeloid leukemia, emphasizing the need for multidisciplinary collaboration and individualized treatment strategies.

Experts on CML

EP. 6: Asciminib in CML Treatment: Efficacy and Responses Shown in the ASCEMBL Study

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS
September 26th 2023

A review of promising results from the ASCEMBL study, highlighting asciminib's superior efficacy, well-tolerated profile, and potential impact on chronic myeloid leukemia treatment options.

Experts on CML

EP. 7: Cross Q&A: Evaluating Ponatinib and Asciminib as 3L Therapy in CML

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS
October 3rd 2023

Considerations for selecting between ponatinib and asciminib as third-line therapies for CML based on factors such as disease burden, mutations, and patient tolerability.

Experts on CML

EP. 8: Olverembatinib in Ponatinib-Resistant CML: Considerations for Later-Line Therapy

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS
October 3rd 2023

Expert insight into the later-line efficacy and tolerability of olverembatinib, a third generation TKI, in ponatinib-resistant, refractory chronic myeloid leukemia populations.

Fred Hutch and City of Hope “Face Off” on Ixazomib Vs Olverembatinib in CML and Multiple Myeloma

EP. 9: Fred Hutch and City of Hope “Face Off” on Ixazomib Vs Olverembatinib in CML and Multiple Myeloma

ONCOLOGY Staff
October 19th 2023

Fred Hutch and City of Hope "Face Off" regarding presentations focusing on multiple myeloma and chronic myeloid leukemia.